The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


LYRINEL XL 5 mg prolonged release tablets



Janssen Sciences Ireland UCPA22612/008/001

Main Information

Trade NameLYRINEL XL 5 mg prolonged release tablets
Active SubstancesOXYBUTYNIN HYDROCHLORIDE
Dosage FormProlonged-release tablet
Licence HolderJanssen Sciences Ireland UC
Licence NumberPA22612/008/001

Group Information

ATC CodeG04BD Drugs for urinary frequency and incontinence
G04BD04 oxybutynin

Status

License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back